Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Invests $3 Million in Soligenix; Finalizes China Oral Mucositis Drug In-licensing

publication date: Sep 12, 2016
SciClone Pharma, a US company that in-licenses drugs for the China market, struck a final deal for rights to a novel treatment for oral mucositis from Soligenix of New Jersey. In return for a $3 million investment into Soligenix, SciClone will have rights to SGX942 in China including Hong Kong and Macau, plus Taiwan, South Korea and Vietnam. The two companies have been collaborating for three years. In 2013, SciClone gave Soligenix access to trial data from its failed oral mucositis treatment in return for China rights. At the end of 2015, SciClone started developing SGX942 in China. The $3 million investment and the expanded list of countries is new information. More details....

Stock Symbols: (NSDQ: SCLN) (OTC: SNGX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here